Surface Oncology, Inc.
SURF · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,016.5% | -97.9% | 721.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -206.2% | -2,828.9% | 48.8% | -373.5% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -217.7% | -2,957.3% | 47% | -345.1% |
| EPS | -1.17 | -1.8 | 1.67 | -1.9 |
| % Growth | 35% | -207.8% | 187.9% | – |
| EPS Diluted | -1.17 | -1.8 | 1.57 | -1.9 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -206.2% | -2,828.9% | 48.8% | -373.5% |